Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHRONOS: 24 vs 48 Weeks of Peginterferon alfa-2a and Ribavirin in HIV/HCV Co-infected Patients
NCT00611819Phase 4Unknown
- Sponsor
- UVEG
- Start
- Nov 2005
- Primary completion
- Apr 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of peginterferon alfa-2a, ribavirin in hepatitis C (HCV), sponsored by UVEG. Status: unknown.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00611819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611819.